Does Medicaid Cover Zepbound or Wegovy? What Changes in Pregnancy and Postpartum

The short answer

Only if your state chooses to. Federal law lets each Medicaid program decide whether to cover drugs used for weight loss, and in January 2026 just 13 states did¹. Two of those have since stopped. Every state must cover GLP-1s for diabetes, and must cover Wegovy for heart risk and Zepbound for sleep apnea¹.

Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Every clinical figure here is cited inline to its primary source, the trial or the FDA label, so you can check it. This is background reading, not medical advice.

Medicaid vs Medicare, side by side

People mix these two up constantly, and the rules are opposite in shape. Medicaid is run by your state, so the answer changes at the state line. Medicare is federal, and its weight-loss route is a temporary program that is the same everywhere.

If you are on Medicare, our cost guide covers the Medicare GLP-1 Bridge in full. In short, since July 1, 2026 eligible Part D enrollees pay $50 a month for Foundayo, Wegovy (injection or tablets) or the Zepbound KwikPen, through December 31, 2027. People with both Medicare and Medicaid can use it if their Part D plan qualifies.

Which states cover GLP-1s for weight loss in October 2026

This table lists only what we read on each state's own drug list, prior-authorization criteria or provider notice in October 2026. "Covered" always means prior authorization: your prescriber has to send the plan your BMI and history before the first fill. Where we could not read a current official source, the row says so.

Two patterns stand out. The drug your state prefers is the one you will usually be asked to try first, and it differs: Missouri and Wisconsin put Zepbound and Foundayo first, while Delaware and Tennessee prefer both Wegovy and Zepbound^4,8,9,11. And coverage is moving in one direction. Four states left in January, Massachusetts followed in July and Rhode Island this month, Rhode Island citing its state budget^1,12,13.

North Carolina shows how fast this can swing. It ended obesity coverage on October 1, 2025 over a budget standoff and restored it that December¹. Its October 2026 list now includes Foundayo, Wegovy HD and the Zepbound KwikPen³. The same list tells managed care plans they may not add their own extra prior-authorization rules to this drug class, so if a private company manages your Medicaid plan, it should apply the state's criteria and nothing stricter³.

Preferred status matters more than it looks. In Delaware, you need to have tried two preferred products before a non-preferred one will be approved, which puts Foundayo behind the injections there⁴. Virginia lists the GLP-1s as non-preferred in a closed class, so each one goes through its own authorization form¹⁰. If your prescriber asks for a non-preferred drug first, expect a request for a reason.

What prior authorization usually asks for

In the states that cover these drugs, the paperwork looks similar, and knowing it in advance saves a denial. Minnesota's criteria are typical: a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol, plus documented diet and activity changes and a recorded starting weight⁶. Mississippi uses the same BMI lines for adults and allows one obesity drug at a time⁷.

Renewal is where many approvals end. Minnesota first approves Wegovy for six months and renews only if you have lost at least 5% of your starting weight⁶. Missouri approves four weeks at a time while the dose is being raised, so each step needs a new approval until you reach a maintenance dose⁸. Michigan asks the prescriber to attest that every other reasonable weight-loss approach has already failed⁵.

For a mother, the practical move is to keep a simple record before the first appointment: your starting weight and BMI, any blood pressure or blood sugar readings, and what you have already tried. Bring it to the visit so your prescriber can attach it on the first request rather than the appeal.

Pregnancy and postpartum Medicaid: 12 months, and what it doesn't add

Medicaid pays for about 4 in 10 births in the United States². Federal law guarantees pregnancy coverage only through 60 days after birth, but a permanent federal option lets states extend it to 12 months. As of July 2026, KFF counts 49 states plus DC with the 12-month extension in place; Arkansas is the exception².

That extra time matters for a GLP-1 decision, because most mothers who want one are not ready in the first six weeks. The catch is that postpartum Medicaid keeps you on the same benefit package your state already offers. It does not add weight-loss drug coverage in a state that excludes it. In Mississippi, the criteria go further and rule out obesity drugs during pregnancy and while breastfeeding⁷. It also has an end date. After the postpartum period, some mothers qualify for Medicaid another way, but others lose coverage, especially in states that did not expand Medicaid². If you are planning around a 12-month window, ask your caseworker which group you move into afterward.

The labels point the same way during pregnancy: these drugs are stopped when a pregnancy is recognized, and our guide to GLP-1s and pregnancy has the detail. Breastfeeding splits by form. Wegovy injection labeling describes missing milk data; Zepbound includes a milk-transfer study but no infant-outcome data. The choice still means weighing the benefits of breastfeeding against your own need for the drug. Every GLP-1 pill, Foundayo and the Wegovy tablet included, is not recommended while nursing. Our breastfeeding guide and postpartum timing guide cover when starting makes sense.

Ozempic on Medicaid needs a type 2 diabetes diagnosis

Ozempic is approved for type 2 diabetes, and every state Medicaid program has to cover GLP-1s for that use¹. So a mother with type 2 diabetes, including diabetes that persisted after gestational diabetes, can usually get Ozempic or Mounjaro through Medicaid in any state, subject to the state's drug list. Without that diagnosis, Ozempic for weight loss is off-label, and states that cover weight loss steer you to Wegovy or Zepbound instead. Our page on GLP-1s after gestational diabetes explains how that history changes the picture.

Zepbound for sleep apnea and Wegovy for heart disease

These are the routes that work in every state. Since 2024, Medicaid has had to cover Wegovy to lower cardiovascular risk and Zepbound for moderate to severe obstructive sleep apnea in adults with obesity¹. Massachusetts, which ended weight-loss coverage, kept exactly these uses, plus liver disease (MASH), with a BMI above 27 for heart disease and above 30 for sleep apnea¹².

If you snore, wake unrefreshed or have been told you stop breathing at night, a sleep study is worth asking for on its own merits, and it may also open a covered route. Our guide to sleep apnea in women explains why it is so often missed in mothers.

What about the federal BALANCE program?

CMS has a voluntary model, called BALANCE, meant to widen Medicaid coverage of GLP-1s for weight loss, starting May 2026¹. Joining is up to each state. As of early October 2026, CMS had not published a list of participating states, so it is not a reason to expect coverage yet.

How to check your own state

Search your state Medicaid agency's preferred drug list for "weight management" or "anti-obesity", not for a brand name. If you are in a managed care plan, call the member services number on your card and ask two questions: is the drug on the formulary for weight loss, and what does prior authorization require. Write down the date and the name of the person you spoke with.

If Medicaid says no

Ask for the denial in writing and check whether a covered use fits you. If none does, self-pay is the fallback. Wegovy pen runs $349 a month from Novo Nordisk, the Wegovy pill starts at $149, and Foundayo starts at $149. Zepbound KwikPen starts at $299 and is $449 at maintenance doses if you refill within 45 days. Our cost guide has every dose, and the lowest-cost programs board compares telehealth options.

How solid is this?

This page rests on administrative records, not trials: each state's drug list, criteria or notice, read directly in October 2026, and KFF's survey data for the national count. That makes the facts precise but short-lived. Two states changed course in the last three months alone. Treat the table as a dated reading and confirm with your state Medicaid plan or prescriber before you count on coverage.